NCT02269852View on ClinicalTrials.gov

The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

June 30, 2014

Conditions
Influenza
Interventions
BIOLOGICAL

trivalent seasonal influenza vaccine

"* Infants: 0.25 ml/ dose;~* Adults: 0.5 ml/ dose;~* Seniors: 0.5 ml/ dose;"

Trial Locations (1)

Unknown

Guzhen Center for Diseases Control and Prevention, Bengbu

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT02269852 - The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine | Biotech Hunter | Biotech Hunter